TSE:4502Pharmaceuticals
Takeda Pharmaceutical (TSE:4502): Reassessing Valuation After Landmark Actos RICO Class Action Ruling
Takeda Pharmaceutical (TSE:4502) is back in the spotlight after the Ninth Circuit upheld a landmark civil RICO class action over alleged concealment of bladder cancer risks tied to its former diabetes blockbuster, Actos.
See our latest analysis for Takeda Pharmaceutical.
Despite the overhang from the Actos litigation, Takeda’s share price has held up reasonably well, with a 1 month share price return of 7.44% and a 1 year total shareholder return of 14.13%. This suggests sentiment is still...